TMCnet News
Mirata BioPharma, LLC Receives Top Honors at the 6th Annual Texas Life Science ForumMirata BioPharma, LLC was recognized as one of the Rice Alliance 10 Most Promising Life Science Companies at the 2017 Texas Life Science Forum hosted by the Rice Alliance for Technology and Entrepreneurship, BioHouston and TMC (News - Alert) Innovation at the BioScience Research Collaborative in Houston, November 7, 2017. The companies were chosen by industry experts and investors. Mirata Biopharma LLC is an immuno-oncology company that is developing a breakthrough targeted recombinant fusion protein platform that utilizes the body natural defenses to combat cancer. The Company's Targeted Granzyme B Immunotherapy technology is versatile and has broad therapeutic applications. The platform consists of three biopharmaceutical compounds licensed from Research Development Foundation (a supporting organization for the Clayton Foundation for Research), a Texas-based non-profit organization dedicated to fund research and development to eradicate cancer and Mirata has right of first refusal for any other therapeutic from this class of compounds. "Mirata BioPharma is poised to transform the treatment of cancer with this new class of immuno-oncology therapeutics. Our Granzyme B compounds represent the next generation(s) of targeted immuno-oncology therapeutics. The antibody targeting component of the fusion protein can be changed out to target cancers expressing specific ell surface receptors, thus broadening the utility of this platform to treatment of multiple types of cancers," said Keizo Koya PhD, CEO of Mirata BioPharma, LLC. "We are honored to be selected as one of the '10 Most Promising' Life Science Companies' by the Rice Alliance for Technology and Entrepreneurship, BioHouston and TMC Innovation." More than 55 startup companies presented their four-minute business plans at the forum. An additional two Nasdaq-listed life science companies provided status updates. "Every year the quality of companies improves," said Rice Alliance Managing Director Brad Burke, who announced the winners at the event. "This year we had a diversity of companies, both in offerings as well as maturity. We highlighted 55 startups in addition to six more mature Nasdaq listed companies. These companies demonstrated the diversity of innovation, talent, investment, potential and success in the life science industry." The event is one of the largest life science venture capital conferences in the Southwest and featured more than 35 industry and investment speakers. Among the 500 attendees were venture capitalists and other investors, entrepreneurs, industry representatives, business leaders and service providers. ABOUT MIRATA BIOPHARMA, LLC Mirata BioPharma, LLC is a pre-clinical stage immuno-oncology company founded in January 2017. The Company entered into a license agreement with Research Development Foundation, a nonprofit supporting organization of the Clayton Foundation for Research ("Clayton Foundation") to develop three drug candidates based on the Targeted Granzyme B Immunotherapy (TGI) platform. The TGI platform was developed by a team of Clayton Foundation investigators headed by Michael Rosenblum, PhD. Dr. Rosenblum's research is in developing targeted immunotherapeutic approaches that maximize anti-tumor efficacy while minimizing immunosuppressive side effects. He is on the Scientific Advisory Board of Mirata BioPharma.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171213006128/en/ |
